A group of direct lenders including Ares Management (ARES) and HPS Investment Partners is providing a $3B credit facility to finance Carlyle Group’s (CG) potential purchase of Baxter’s (BAX) kidney-care division, John Sage of Bloomberg reports, citing people with knowledge of the matter. The debt package would include a $2.5 billion unitranche loan and a $450M revolver, said the people.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX:
- Baxter downgraded to Underweight from Equal Weight at Morgan Stanley
- Baxter price target lowered to $37 from $38 at Citi
- Baxter call volume above normal and directionally bullish
- Baxter up 5% after WSJ report on Carlyle talks to buy kidney care unit
- Carlyle in talks to buy Baxter’s Vantive business for over $4B, WSJ reports